Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Streptozotocin
38
CHF
CHF 38.00
In stock
AG-CN2-0046-M05050 mgCHF 38.00
AG-CN2-0046-M250250 mgCHF 55.00
AG-CN2-0046-G0011 gCHF 140.00
| Product Details | |
|---|---|
| Synonyms | 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; Streptozocin; STZ; NSC 85998; Antibiotic U9889; Zanosar |
| Product Type | Chemical |
| Properties | |
| Formula |
C8H15N3O7 |
| MW | 265.2 |
| Merck Index | 14: 8832 |
| CAS | 18883-66-4 |
| RTECS | LZ5775000 |
| Purity Chemicals |
≥98% (HPLC) ≥75% (α anomer) |
| Appearance | Off-white to pale yellow powder. |
| Solubility | Soluble in water or ethanol. |
| Identity | Determined by UV and IR. |
| Other Product Data |
Note: Once the compound is in solution it spontaneously releases NO gas at room temperature. We recommend to prepare fresh solutions immediately before use. |
| InChi Key | ZSJLQEPLLKMAKR-GKHCUFPYSA-N |
| Smiles | CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep under inert gas. Protect from light. Protect from moisture and oxygen. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Antibiotic [1].
- Diabetogenic. Diabetes inducer. Induces diabetes mellitus in animal models through its toxic effects on pancreatic β-cells [2, 5, 13, 14].
- Mutagenic [3, 10].
- Potent alkylating agent. Potent DNA methylating agent [4, 10].
- Nitric oxide (NO) donor. Vasorelaxant [6].
- Cytotoxic to cells that express GLUT2 glucose transporter [7].
- O-GlcNAc-selective N-acetyl-β-D-glucosaminidase (O-GlcNAcase) inhibitor [8].
- Genotoxic. Induces DNA damage. Produces DNA strand breaks [9, 10]. Cell death inducer [15].
- Antineoplastic. Anti-cancer agent used in chemotherapy [10, 11].
- Induces cell cylce arrest at G2 [12].
Product References
- Streptozotocin, a new antibacterial antibiotic: J.J. Vavra, et al.; Antibiot. Ann. 7, 230 (1959)
- Studies on the diabetogenic action of Streptozotocin: N. Raketien, et al.; Cancer Chemother. Rep. 29, 91 (1963)
- Mutagenic activity of Streptozotocin: S.M. Kolbye & M.S. Legator; Mutat. Res. 6, 387 (1968)
- Alkylation of DNA in rat tissues following administration of streptozotocin: R.A. Bennett & A.E. Pegg; Cancer Res. 41, 2786 (1981)
- Streptozotocin interactions with pancreatic beta cells and the induction of insulin-dependent diabetes: G.L. Wilson & E.H. Leiter; Curr. Top. Microbiol. Immunol. 156, 27 (1990) (Review)
- Nitric oxide generation from streptozotocin: N.S. Kwon, et al.; FASEB J. 8, 529 (1994)
- STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells: W.J. Schnedl, et al.; Diabetes 43, 1326 (1994)
- Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death: K. Liu, et al.; PNAS 97, 2820 (2000)
- Chromosomal response of human lymphocytes to Streptozotocin: A.D. Bolzan & M.S. Bianchi; Mutat. Res. 503, 63 (2002)
- Genotoxicity of streptozotocin: A.D. Bolzan & M.S. Bianchi; Mutat. Res. 512, 121 (2002) (Review)
- Clastogenic effects of streptozotocin on human colon cancer cell lines with gene amplification: A.D. Bolzan & M.S. Bianchi; J. Environ. Pathol. Toxicol. Oncol. 22, 281 (2003)
- Streptozotocin induces G2 arrest in skeletal muscle myoblasts and impairs muscle growth in vivo: A.P. Johnston, et al.; Am. J. Physiol. Cell Physiol. 292, C1033 (2007)
- The mechanisms of alloxan- and streptozotocin-induced diabetes: S. Lenzen; Diabetologia 51, 216 (2008)
- Mechanisms of toxic effect of streptozotocin on β-cells in the islets of langerhans: V.B. Pisarev, et al.; Bull. Exp. Biol. Med. 148, 937 (2009)
- The role of programmed cell death in streptozotocin-induced early diabetic nephropathy: W.H. Wu, et al.; J. Endocrinol. Invest. 34, e296 (2011)
- Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes: H.H. Ng, et al.; Sci. Rep. 7, 39604 (2017)
- SOCS-1 inhibition of type I interferon restrains Staphylococcus aureus skin host defense: N. Klopfenstein, et al.; PLoS Pathog. 17, e1009387 (2021)
- Relaxin elicits renoprotective actions accompanied by increasing bile acid levels in streptozotocin-induced diabetic mice: CH. Leo, et al.; Biomed. Pharmacother. 162, 114578 (2023)
Related Products
